New Drug Approvals Archive - February 2003
Cardizem LA (diltiazem hydrochloride) Extended-Release Tablets
Date of Approval: February 6, 2003
Company: Biovail Laboratories Incorporated
Treatment for: Hypertension, Angina Pectoris
Cardizem LA is an extended-release formulation of diltiazem for indicated for the once-daily treatment of hypertension and for the management of chronic stable angina.
Oxytrol (oxybutynin) Transdermal System
Date of Approval: February 26, 2003
Company: Allergan, Inc.
Treatment for: Overactive Bladder
Oxytrol (oxybutynin) is a transdermal therapy used to treat overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and frequency.
Cardizem LA (diltiazem hydrochloride)
New Indication Approved: April 2, 2004